Clinical Trial Update: Diclofenac for Prevention of Post-ERC Pancreatitis [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 trial is evaluating diclofenac to prevent post-ERCP pancreatitis, and the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatitis
• Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis

Drugs mentioned

• Diclofenac (diclofenac)

Snippet

Sponsor: Karolinska Institutet | Conditions: Common Bile Duct Diseases | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING